This article is more than 5 years old. Information may no longer be current.

Oxurion releases phase 1/2 data of clinical study evaluating TR-317 for DME

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

THR-317 for the treatment of diabetic macular edema met its primary safety endpoint in a phase 1/2 study and also demonstrated efficacy, according to a press release from Oxurion.

Anat Loewenstein, MD , MHA, professor of ophthalmology, chair of the ophthalmology division at Tel Aviv Medical Center, presented the clinical-stage data at FLORetina 2019. Two dose levels, 4 mg and 8 mg, of the anti-placental growth factor candidate THR-317 were evaluated for safety and efficacy in 49 patients with DME, including anti-VEGF-naive patients and suboptimal anti-VEGF responders.

Both groups met the primary endpoint for safety, but patients who received the 8-mg dose achieved better visual acuity outcomes compared with the 4-mg dose group.

At day 90 of the study, 30 days after the last injection, topline data demonstrated THR-317 was safe and well tolerated. Thirty percent of anti-VEGF-naive patients achieved a 15-letter vision gain in best corrected visual acuity. At day 150, 30% of patients in the 8-mg anti-VEGF-naive group achieved a 10 letter or greater vision gain and 10% achieved a 15 letter or greater vision gain.